These findings highlighted the clinical relevance of KIR-HLA interactions and contributed to the growing interest in incorporating NK cell alloreactivity, through donor KIR typing and recipient HLA ligand analysis, into donor selection strategies for mismatched HSCT, particularly in AML cases. This evidence concerns the gene KIR3DL1 and acute myeloid leukemia.